COMMUNIQUÉS West-GlobeNewswire
-
Trethera Announces Massachusetts General Hospital Clinical Trial Collaboration to Evaluate TRE-515 in ALS Patients
31/03/2026 -
Catheter Precision Reports 2025 Results and Updates on Strategic Expansion
31/03/2026 -
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
31/03/2026 -
Lighthouse Autism Center Opening New Autism Therapy Center in Rocky Mount, North Carolina
31/03/2026 -
Berry Street Joins Amazon's Health Benefits Connector, Expanding Access to one of Healthcare's Most Underutilized Benefits
31/03/2026 -
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
31/03/2026 -
Alabama Attorney General Steve Marshall Champions The Helios Alliance's Project RenewAL to Advance Statewide Opioid Abatement
31/03/2026 -
Spinal Rehab & Sports Medicine Expands Impact in Austin with Elite University Partnerships and Growing Presence Across Local Athletic Communities
31/03/2026 -
TimelyCare Lands Fifth Straight Appearance on Inc. Fastest-Growing Companies in the Southwest list
31/03/2026 -
Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors
31/03/2026 -
New Cost Impact Model Highlights Potential for Monthly Injectable Buprenorphine to Reduce Staffing Burdens in Correctional Facilities
31/03/2026 -
Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020 and Strengthens Leadership to Support Next Phase of Growth
31/03/2026 -
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
31/03/2026 -
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
31/03/2026 -
Fennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
31/03/2026 -
SCYNEXIS Announces $40.0 Million Private Placement
31/03/2026 -
LENSAR® Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
31/03/2026 -
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
31/03/2026 -
Beta Bionics Introduces Bionic Insights™ in Bionic Reports — Transforming How Clinicians Understand and Optimize Diabetes Care
31/03/2026
Pages